Business Description
NexgenRx Inc
NAICS : 621610
SIC : 8639
ISIN : CA65337X1042
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.71 | |||||
Equity-to-Asset | 0.26 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | 0.36 | |||||
Interest Coverage | 3.13 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.05 | |||||
Beneish M-Score | -2.53 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.6 | |||||
3-Year EBITDA Growth Rate | -27.9 | |||||
3-Year FCF Growth Rate | -10.6 | |||||
3-Year Book Growth Rate | 14.7 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 70.76 | |||||
9-Day RSI | 64.33 | |||||
14-Day RSI | 62.67 | |||||
6-1 Month Momentum % | -3.51 | |||||
12-1 Month Momentum % | 10 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.08 | |||||
Quick Ratio | 1.08 | |||||
Cash Ratio | 0.08 | |||||
Days Sales Outstanding | 18 | |||||
Days Payable | 104.08 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 3.33 | |||||
Forward Dividend Yield % | 3.33 | |||||
5-Year Yield-on-Cost % | 3.33 | |||||
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | 2.89 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 78.13 | |||||
Operating Margin % | 1.3 | |||||
Net Margin % | 0.56 | |||||
FCF Margin % | 8.8 | |||||
ROE % | 1.05 | |||||
ROA % | 0.29 | |||||
ROIC % | -19.1 | |||||
ROC (Joel Greenblatt) % | 6.57 | |||||
ROCE % | 0.77 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | N/A | |||||
PE Ratio without NRI | N/A | |||||
Price-to-Owner-Earnings | 25 | |||||
PS Ratio | 1.36 | |||||
PB Ratio | 3.41 | |||||
Price-to-Tangible-Book | 10 | |||||
Price-to-Free-Cash-Flow | 15 | |||||
Price-to-Operating-Cash-Flow | 12.5 | |||||
EV-to-EBIT | 327.35 | |||||
EV-to-EBITDA | 16.03 | |||||
EV-to-Revenue | 1.41 | |||||
EV-to-FCF | 16 | |||||
Price-to-Projected-FCF | 1.2 | |||||
Price-to-Median-PS-Value | 0.7 | |||||
Earnings Yield (Greenblatt) % | 0.31 | |||||
FCF Yield % | 6.34 | |||||
Forward Rate of Return (Yacktman) % | 8.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
NexgenRx Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | 15.342 | ||
EPS (TTM) (C$) | 0 | ||
Beta | 0.42 | ||
Volatility % | 40.96 | ||
14-Day RSI | 62.67 | ||
14-Day ATR (C$) | 0.004707 | ||
20-Day SMA (C$) | 0.2875 | ||
12-1 Month Momentum % | 10 | ||
52-Week Range (C$) | 0.175 - 0.345 | ||
Shares Outstanding (Mil) | 70.92 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
NexgenRx Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
NexgenRx Inc Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
NexgenRx Inc Frequently Asked Questions
What is NexgenRx Inc(TSXV:NXG)'s stock price today?
When is next earnings date of NexgenRx Inc(TSXV:NXG)?
Does NexgenRx Inc(TSXV:NXG) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |